BTAI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 107592 min ago

@ $3.11

Išleistas: 14 vas. 2024 @ 20:43

Grąža: -15.43%

Ankstesnis signalas: vas. 14 - 18:27

Ankstesnis signalas: Pardavimas

Grąža: 3.15 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology...

Stats
Šios dienos apimtis	260 297
Vidutinė apimtis	1.54M
Rinkos kapitalizacija	97.40M
EPS	$0 ( 2024-03-12 )
Kita pelno data	( $-0.730 ) 2024-06-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.430
ATR14	$0.00600 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	O'neill Vincent	Sell	2 250	Restricted Stock Units
2024-03-15	O'neill Vincent	Buy	2 250	Common Stock
2024-04-04	O'neill Vincent	Sell	165	Common Stock
2024-03-14	O'neill Vincent	Sell	521	Restricted Stock Units
2024-03-14	O'neill Vincent	Buy	521	Common Stock

INSIDER POWER
-8.71
Last 87 transactions
Buy: 187 774 \| Sell: 228 648

Tūris Koreliacija

Ilgas: 0.12 (neutral)

Trumpas: 0.88 (strong)

Signal:(62.671) Same movement expected

BioXcel Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AGNC	0.927
NWL	0.905
BOCH	0.904
PRAX	0.896
YQ	0.896
SLVO	0.894
GRFS	0.893
SHYF	0.891
CASS	0.888
CLPS	0.888

10 Labiausiai neigiamai susiję koreliacijos
CRSA	-0.937
LONE	-0.906
PPBT	-0.903
SNCR	-0.902
TSLA	-0.897
MVBF	-0.882
TLMD	-0.88
EPZM	-0.878
RMRM	-0.876
MTEK	-0.876

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

BioXcel Therapeutics Inc Koreliacija - Valiuta/Žaliavos

-0.92
( very strong negative )

0.00
( neutral )

-0.85
( strong negative )

0.59
( weak )

0.85
( strong )

BioXcel Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$1.38M
Bruto pelnas:	$-198 000 (-14.35 %)
EPS:	$-6.15

FY	2023
Pajamos:	$1.38M
Bruto pelnas:	$-198 000 (-14.35 %)
EPS:	$-6.15

FY	2022
Pajamos:	$375 000
Bruto pelnas:	$355 000 (94.67 %)
EPS:	$-6.13

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.